Figure 2

Estimated mean change from baseline over time on ADAS-cog 11, CDR-sb and ADCS-ADL for patients with mild Alzheimer’s disease defined as either MMSE ≥20 (Panels A, B and C) or ADAS-cog ≤19 (Panels D, E, F) at baseline. Error bars represent one standard error. (A) ADAS-cog treatment-placebo difference at 18 months = 3.3, p = 0.024, Baseline MMSE ≥ 20; (B) CDR-sb treatment-placebo difference at 18 months = 0.72, p = 0.053, Baseline MMSE ≥ 20; (C) ADCS-ADL treatment – placebo difference at 18 months = 2.2, p = 0. 3, Baseline MMSE ≥ 20 (D) ADAS-cog treatment-placebo difference at 18 months = 5.9, p < 0.008, Baseline ADAS-cog ≤ 19; (E) CDR-sb treatment-placebo difference at 18 months = 1, p = 0.08, Baseline ADAS-cog ≤ 19; (F) ADCS-ADL treatment-placebo difference at 18 months = 4.92, p = 0.07, Baseline ADAS-cog ≤ 19.